UroGen Pharma

Open enrollment with a later-stage pipeline tilt

According to ClinicalTrials.gov-derived indexes, UroGen Pharma sits in the top decile of US sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count).

9 total trials 2 currently recruiting 4 completed later-stage tilt top decile by trial count

UroGen Pharma: 9 sponsored US clinical trials, 2 recruiting.

UroGen Pharma sponsors 9 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 4 completed. 6 of these trials are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Urothelial Carcinoma, with 5 trials.

Top-decile sponsor footprint

UroGen Pharma ranks in the top decile of sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

9 total, page 1 of 1

RECRUITING Phase 3

A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer

NCT06774131
RECRUITING

uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto

NCT05874921
ACTIVE NOT RECRUITING Phase 3

A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer

NCT06331299
ACTIVE NOT RECRUITING Phase 3

A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

NCT05243550
COMPLETED Phase 1

A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)

NCT05375903
COMPLETED Phase 3

Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle Invasive Bladder Cancer (NMIBC)

NCT05136898
TERMINATED Phase 3

A Phase 3 Study of UGN-102 for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

NCT04688931
COMPLETED Phase 2

A Phase 2b Study of UGN-102 for Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer

NCT03558503
COMPLETED Phase 3

The OLYMPUS Study - Optimized DeLivery of Mitomycin for Primary UTUC Study

NCT02793128

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 1
Phase 3 6

Therapeutic Areas

Urothelial Carcinoma 5
Urothelial Carcinoma Bladder 3
Bladder Cancer 3
Transitional Cell Carcinoma of Renal Pelvis 2
Carcinoma, Transitional Cell 2
Urothelial Carcinoma of the Renal Pelvis and Ureter 1
Urothelial Cancer of Renal Pelvis 1
Urothelial Carcinoma Ureter Recurrent 1
Urothelial Carcinoma Ureter 1
Urothelial Carcinoma Recurrent 1

Where UroGen Pharma enrollment is open (later-stage tilt)

2 recruiting of 9 indexed (22% open); 4 completed (44%).

Phase mix: 6 late (III/IV) vs 2 early (I/II) (later-stage heavy).

Top condition: Urothelial Carcinoma (5 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

UroGen Pharma: open-pipeline peers nationwide

Peers matched on 9 registered trials and 22% open enrollment, not the therapeutic-area sidebar.

UroGen Pharma sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 8101214161820 0%10%20%30%40%50% Total trials Recruiting share UroGen Pharma4D Molecular Therapeutics9 Meters BiopharmaAadi BioscienceAblynx, a Sanofi companyALX OncologyBiosense WebsterEnglewood Hospital and Medical CenterEnsysce Biosciences
UroGen Pharma sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

UroGen Pharma sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 9 trials (± recruiting share)

Sponsors near 22% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this UroGen Pharma page

9 registered trials is a research-attention snapshot, not an endorsement of UroGen Pharma or any single study.

  • 2 of UroGen Pharma's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Urothelial Carcinoma is the condition UroGen Pharma studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Urothelial Carcinoma trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

UroGen Pharma pipeline card: 9 registered trials from official public datasets.Report a data error.